Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele
Brain Pathology · 2024
DOI: 10.1111/bpa.13208 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Pathology, 2024. Verfasst von Xiao-Yu Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Guangdong, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Apolipoproteins E. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangdong Special Funds for Science and Technology.
Themen: Demenz
Abstract (Originalsprache)
The apolipoprotein E ɛ4 allele ( APOE4 ) is universally acknowledged as the most potent genetic risk factor for Alzheimer's disease (AD). APOE4 promotes the initiation and progression of AD. Although the underlying mechanisms are unclearly understood, differences in lipid‐bound affinity among the three APOE isoforms may constitute the basis. The protein APOE4 isoform has a high affinity with triglycerides and cholesterol. A distinction in lipid metabolism extensively impacts neurons, microglia, and astrocytes. APOE4 carriers exhibit phenotypic differences from non‐carriers in clinical examinations and respond differently to multiple treatments. Therefore, we hypothesized that phenotypic classification of AD patients according to the status of APOE4 carrier will help specify research and promote its use in diagnosing and treating AD. Recent reviews have mainly evaluated the differences between APOE4 allele carriers and non‐carriers from gene to protein structures, clinical features, neuroimaging, pathology, the neural network, and the response to various treatments, and have provided the feasibility of phenotypic group classification based on APOE4 carrier status. This review will facilitate the application of APOE phenomics concept in clinical practice and promote further medical research on AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Shantou University Medical College, Guangdong, China.
- Brain Function and Disease Laboratory, Shantou University Medical College, Guangdong, China.
- Fudan University Huashan Hospital, Department of Neurosurgery, State Key Laboratory for Medical Neurobiology, Institutes of Brain Science, Shanghai Medical College-Fudan University, Shanghai, China.
- Shantou Longhu People's Hospital, Shantou, Guangdong, China.
ORCID-Profile: Nai-Li Wei
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangdong Special Funds for Science and Technology
- Guangdong Basic and Applied Basic Research Foundation
- First Affiliated Hospital of Shantou University Medical College Supporting Funding
- 2020 Li Ka Shing Foundation Cross-Disciplinary Research
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Ji, X. Y., Peng, X. Y., Tang, H. L., Pan, H., Wang, W. T., Wu, J., Chen, J., & Wei, N. L. (2024). Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele. Brain Pathology. https://doi.org/10.1111/bpa.13208
Vancouver
Ji XY, Peng XY, Tang HL, Pan H, Wang WT, Wu J, et al. Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele. Brain Pathology. 2024. doi:10.1111/bpa.13208
BibTeX
@article{Ji2024,
author = {Ji, Xiao-Yu and Peng, Xin-Yuan and Tang, Hai-Liang and Pan, Hui and Wang, Wei-Tang and Wu, Jie and Chen, Jian and Wei, Nai-Li},
title = {Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele},
journal = {Brain Pathology},
year = {2024},
doi = {10.1111/bpa.13208}
}
EUVIMED